Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

BACKGROUND: In the phase 3 RADIANT-2 study, everolimus plus octreotide long-acting repeatable (LAR) showed improvement of 5.1 months in median progression-free survival versus placebo plus octreotide LAR among patients with advanced neuroendocrine tumors associated with carcinoid syndrome. The progr...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Oncol
Главные авторы: Pavel, M.E., Baudin, E., Öberg, K.E., Hainsworth, J.D., Voi, M., Rouyrre, N., Peeters, M., Gross, D.J., Yao, J.C.
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2017
Предметы:
Gastrointestinal tumor
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360141/
https://ncbi.nlm.nih.gov/pubmed/28444114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx193
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы